Literature DB >> 16469274

Current therapies for neuromuscular manifestations of paraneoplastic syndromes.

Myrna R Rosenfeld1, Josep Dalmau.   

Abstract

The neuromuscular manifestations of paraneoplastic disorders result in diverse syndromes that may also occur in patients without cancer. In general, treatment of these disorders is the same whether or not there is an underlying malignancy. However, when the disorder is believed to be paraneoplastic, the main concern should be prompt detection and treatment of the tumor, as this has been shown to offer the best chance for neurologic stabilization or improvement. The paraneoplastic neuromuscular disorders can be divided into two main categories: those that are directly mediated by antibodies and those that are believed to result from other immune-mediated mechanisms, including cytotoxic T-cell responses with or without association with specific antibodies. For disorders in which the antibodies are pathogenic, therapy is aimed at removing the antibodies. For the other disorders, adjuvant therapies are for the most part empiric and include a variety of immunosuppressant and immunomodulatory agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469274     DOI: 10.1007/s11910-996-0012-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  53 in total

1.  The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab.

Authors:  R Weide; J Heymanns; H Köppler
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

2.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

3.  Neuromyotonia, peripheral neuropathy and myasthenia gravis.

Authors:  P Martinelli; A Patuelli; C Minardi; A Cau; A M Riviera; F Dal Pozzo
Journal:  Muscle Nerve       Date:  1996-04       Impact factor: 3.217

4.  Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies.

Authors:  J C Antoine; J F Mosnier; L Absi; P Convers; J Honnorat; D Michel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

5.  Peripheral neuropathy associated with Castleman's disease.

Authors:  M Donaghy; P Hall; J Gawler; N A Gregson; S Leibowitz; S Jitpimolmard; R H King; P K Thomas
Journal:  J Neurol Sci       Date:  1989-02       Impact factor: 3.181

Review 6.  Stiff-man syndrome updated.

Authors:  T R Lorish; G Thorsteinsson; F M Howard
Journal:  Mayo Clin Proc       Date:  1989-06       Impact factor: 7.616

Review 7.  The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.

Authors:  Marinos C Dalakas
Journal:  Pharmacol Ther       Date:  2004-06       Impact factor: 12.310

8.  Malignant transformation in IgM monoclonal gammopathy of undetermined significance.

Authors:  S Montoto; M Rozman; L Rosiñol; E Nadal; E Giné; M Aymerich; A Ferrer; J Esteve; F Bosch; A López-Guillermo; J Bladé; E Montserrat
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

9.  Severe polyneuropathy: initial manifestation of Castleman's disease associated with POEMS syndrome.

Authors:  A Ku; E Lachmann; R Tunkel; W Nagler
Journal:  Arch Phys Med Rehabil       Date:  1995-07       Impact factor: 3.966

10.  FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.

Authors:  S Younes-Mhenni; M F Janier; L Cinotti; J C Antoine; F Tronc; V Cottin; P J Ternamian; P Trouillas; J Honnorat
Journal:  Brain       Date:  2004-09-10       Impact factor: 13.501

View more
  1 in total

1.  Progress in the management of paraneoplastic neurological disorders.

Authors:  Hamid Sadeghian; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.